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Charles Bonnet syndrome (CBS) is a condition charac-
terized by the manifestation of visual hallucinations in 
patients with severe visual deterioration and no cogni-
tive impairment (1-3). Increasing life expectancy among 
patients, many of whom show significant visual loss sec-
ondary to age-related macular degeneration (AMD) or 
glaucoma, is causing an increase in the incidence of CBS. 
Estimated prevalence of simple visual hallucinations in 
patients with severe visual impairment is 59%, decreasing 
to 15% for complex visual hallucinations. Despite this, 
case studies have shown a prevalence of between 1.84% 
and 3.15%. This is due to lack of awareness on the part 
of doctors, as well as patients’ fear of being diagnosed as 
mentally ill (1-3). There is great variability among published 
data and CBS has not been solely described in visually 
impaired patients of advanced age. Cases have been de-
scribed in patients with good vision (4), young patients with 
low vision (5, 6), and children (7, 8).
METHODS
This article surveys CBS prevalence at the Ophthalmol-
ogy Unit of Hospital Clínico San Carlos (HCSC) in Madrid, 
Spain. A group of 2502 patients who had previously been 
examined at the outpatient unit were considered in the 
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study. They also underwent a comprehensive eye examina-
tion that included visual acuity (VA) measurement, anterior 
pole biomicroscopy, posterior pole examination, intra-
ocular pressure measurement, and study of extrinsic and 
intrinsic ocular motility. All the patients were asked about 
the presence of simple and complex visual hallucinations. 
Those patients with visual hallucinations were referred to 
the Neuroophthalmic Multidisciplinary Unit—formed by the 
ophthalmology, neurology, and psychiatry units at HSCS—
for further study. Diagnosis of CBS was by exclusion, once 
other conditions that can trigger hallucinations had been 
ruled out. Distribution by sex, underlying ocular pathology, 
type of hallucination, evolution period, frequency, and du-
ration were also analyzed.
RESULTS
Prevalence of CBS varies between 1.84% and 3.15% ac-
cording to published data. Our study shows a prevalence 
of 0.47%, rising to 15% when limited to patients with low 
vision. Most of the patients were women (58.3%) over 
80 years of age (58.3%) and had severe visual impair-
ment. All 12 cases had VA below 0.1, mainly caused by 
AMD (58.3%) (Tab. I). Hallucinations were mainly of ani-
mals (50%), in color (58.3%), and moving (75%). Half of the 
patients (50%) had been experiencing hallucinations for a 
year, having 3 or more episodes a day (75%), which would 
last between 3 and 5 minutes (50%) (Tab. II).
DISCUSSION
Charles Bonnet syndrome is characterized by the pres-
ence of visual hallucinations ranging from simple ones 
such as lines and basic geometric shapes to complex and 
structured ones usually in the shape of people, faces, ani-
mals, or trees, though they do not include sound. They can 
be black and white or in color, static or moving (9). They 
last under 10 minutes in most cases and are usually repeti-
tive. Clinical course may be episodic, cyclic, or chronic, 
with duration usually under 12 months, though some cases 
lasting several years have been described.
Although the cause behind the manifestation of hallucina-
tions remains undetermined (10), the deafferentation theo-
ry would be responsible for the onset of CBS. According to 
this theory, reduced or absent stimulation of retinal nerve 
TABLE I -  POPULATION DISTRIBUTION, VISUAL ACUITY, 
AND ASSOCIATED OCULAR PATHOLOGY
Characteristics Values, n (%)
Age, y
 ≤70 0
 71-80 5 (41.6)
 >80 7 (58.3)
Sex
 Female 7 (58.3)
 Male 5 (41.6)
Visual acuity
 ≤ Count fingers 1 m 4 (33.3)
 Count fingers 1 m ≤0.1 8 (66.6)
Associated ocular pathology
 Age-related macular degeneration 7 (58.3)
 Glaucoma 3 (25)
 Cataract 1 (8.3)
 Retinal detachment 1 (8.3)
Other associated pathology
 Hypoacusis 5 (41.6)
 Parkinson disease 1 (8.3)
 Depression 6 (50)
CBS prevalence in general population 12/2502 (0.47)
CBS prevalence in low vision patients 12/80 (15)
CBS = Charles Bonnet syndrome.
cells leads to decreased stimulation of the occipital cortex, 
though not disappearing completely as in amaurosis. Re-
sidual afferents would then trigger the deafferentation phe-
nomenon through histologic, biochemical, and anatomical 
changes to synapses in order to try to compensate for the 
limited stimulation, thus becoming hyperexcitable (10). On-
set of CBS has been associated with specific triggering 
factors such as fatigue, stress, low lighting, and dazzling 
lights (10). Charles Bonnet syndrome has also been linked 
to social isolation, cognitive defects, sensory deprivation, 
and low-quality social interaction (11, 12). Hallucinations 
were not triggered by any external factors in 58.3% of the 
patients in our study. Furthermore, the same percentage of 
patients, 58.3%, did not show any other associated factors 
such as social isolation or sensory deprivation (Tab. II).
Patients with CBS do not show any cognitive deficiency or 
any other type of sensory hallucination because it is not a 
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Visual loss and advanced age are the 2 main triggering fac-
tors of this condition. Visual loss is mainly caused by AMD, 
cataract, and glaucoma. The main associated patholo-
gies in our study are AMD (58.3%) and glaucoma (25%) 
(Tab. I). Charles Bonnet syndrome has also been associ-
ated with ocular treatments such as photodynamic (14) or 
antiangiogenic (15) therapies; treatment with topical drugs 
such as brimonidine (16) and systemic drugs (17); neuro-
surgery (18); and systemic pathology (19). Charles Bonnet 
syndrome has also been described in patients with good 
vision (4) and glaucoma (20), the latter possibly related to 
deafferentation of injured fibers even if central vision is pre-
served. Development of CBS may be linked to onset of 
dementia, a risk that may be up to 20 times higher than in 
the rest of the population (21).
Treatment of CBS must be comprehensive, must be in-
dividually tailored, and must cover all of those aspects 
related to the etiopathology of the syndrome. Providing 
patients and their families with adequate information, im-
proving their quality of life, treating the cause if possible, 
or treating secondary anxiety disorder are all critical in 
achieving comprehensive treatment. Regarding medical 
treatment, there is a wide range of therapeutic options 
that cover all aspects related to the pathogenesis of 
CBS (22, 23).
In conclusion, prevalence of CBS at HCSC is 0.47%, rising 
to 15% among patients with low vision. New studies on 
CBS are needed in order to understand all of the variables 
associated with this complex syndrome. Collaborative 
work in a multidisciplinary unit encompassing the fields of 
ophthalmology, neurology, and psychiatry has proved to 
be more efficient as it encompasses all the characteristics 
and aspects associated with CBS.
Financial Support: No financial support was received for this 
submission.
Conflict of Interest Statement: None of the authors has conflict of 
interest with this submission.
Address for correspondence:
Enrique Santos Bueso, MD, PhD
Servicio de Oftalmología
Hospital Clínico San Carlos




TABLE II -  FEATURES OF HALLUCINATIONS AND TRIGGER-
ING AND ASSOCIATED FACTORS IN CHARLES 
BONNET SYNDROME
Characteristics Values, n (%)
Characteristics of hallucinations
 Color 7 (58.3)
 Black and white 5 (41.6)
Type of hallucination
 People 1 (8.3)
 Plants/trees 4 (33.3)
 Animals 6 (50)
 Other 1 (8.3)
Movement
 Moving 9 (75)
 Static 3 (25)
Development period, mo
 ≤1 1 (8.3)
 1-3 2 (16.7)
 3-6 3 (25)
 6-12 6 (50)
Frequency, episodes/d
 1 3 (25)
 3 9 (75)
Duration, min
 ≤1 1 (8.3)
 1-2 1 (8.3)
 3-5 6 (50)
 6-10 1 (8.3)
 11-15 3 (25)
Triggers
 None 7 (58.3)
 Dazzling lights 3 (25)
 Low light 2 (16.7)
Associated factors
 None 7 (58.3)
 Social isolation 2 (16.7)
 Sensory deprivation 3 (25)
psychiatric disorder. Noncoexistence with any other sen-
sory hallucination is crucial, since it would imply a psychi-
atric pathology otherwise. However, CBS plus has been 
described in patients with vision impairment and hypoacu-
sis. These patients describe hearing musical sounds that 
they recognize as unreal (13).
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